GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (OTCPK:DSKYF) » Definitions » Cyclically Adjusted Revenue per Share

Daiichinkyo Co (Daiichinkyo Co) Cyclically Adjusted Revenue per Share : $3.91 (As of Mar. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Daiichinkyo Co Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Daiichinkyo Co's adjusted revenue per share for the three months ended in Mar. 2024 was $1.490. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $3.91 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Daiichinkyo Co's average Cyclically Adjusted Revenue Growth Rate was 9.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 6.20% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 3.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Daiichinkyo Co was 6.20% per year. The lowest was 0.90% per year. And the median was 1.40% per year.

As of today (2024-04-28), Daiichinkyo Co's current stock price is $31.85. Daiichinkyo Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $3.91. Daiichinkyo Co's Cyclically Adjusted PS Ratio of today is 8.15.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Daiichinkyo Co was 9.50. The lowest was 1.68. And the median was 5.17.


Daiichinkyo Co Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Daiichinkyo Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daiichinkyo Co Cyclically Adjusted Revenue per Share Chart

Daiichinkyo Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.42 4.40 3.97 3.99 3.91

Daiichinkyo Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.99 3.66 3.74 3.81 3.91

Competitive Comparison of Daiichinkyo Co's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - General subindustry, Daiichinkyo Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Daiichinkyo Co's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Daiichinkyo Co's Cyclically Adjusted PS Ratio falls into.



Daiichinkyo Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Daiichinkyo Co's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.49/107.2000*107.2000
=1.490

Current CPI (Mar. 2024) = 107.2000.

Daiichinkyo Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.990 98.000 1.083
201409 0.950 98.500 1.034
201412 1.049 97.900 1.149
201503 0.883 97.900 0.967
201506 0.913 98.400 0.995
201509 0.966 98.500 1.051
201512 1.119 98.100 1.223
201603 0.982 97.900 1.075
201606 1.113 98.100 1.216
201609 1.051 98.000 1.150
201612 1.192 98.400 1.299
201703 0.980 98.100 1.071
201706 1.081 98.500 1.176
201709 1.042 98.800 1.131
201712 1.209 99.400 1.304
201803 1.053 99.200 1.138
201806 1.053 99.200 1.138
201809 1.013 99.900 1.087
201812 1.172 99.700 1.260
201903 1.047 99.700 1.126
201906 1.184 99.800 1.272
201909 1.100 100.100 1.178
201912 1.306 100.500 1.393
202003 1.072 100.300 1.146
202006 1.131 99.900 1.214
202009 1.183 99.900 1.269
202012 1.281 99.300 1.383
202103 1.068 99.900 1.146
202106 1.250 99.500 1.347
202109 1.258 100.100 1.347
202112 1.287 100.100 1.378
202203 1.028 101.100 1.090
202206 1.091 101.800 1.149
202209 1.191 103.100 1.238
202212 1.315 104.100 1.354
202303 1.288 104.400 1.323
202306 1.294 105.200 1.319
202309 1.324 106.200 1.336
202312 1.618 106.800 1.624
202403 1.490 107.200 1.490

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Daiichinkyo Co  (OTCPK:DSKYF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Daiichinkyo Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=31.85/3.91
=8.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Daiichinkyo Co was 9.50. The lowest was 1.68. And the median was 5.17.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Daiichinkyo Co Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Daiichinkyo Co's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Daiichinkyo Co (Daiichinkyo Co) Business Description

Industry
Traded in Other Exchanges
Address
3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2021, approximately half of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first U.S approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.